CLOV Clover Health Investments Corp

Clover Health Investments (CLOV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's ...

Chamath Palihapitiya is back with a new SPAC filing. A look back at the 18 SPACs Chamath Palihapitiya has been involved with and the return for investors. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here →

Venture capitalist Chamath Palihapitiya, once dubbed the "SPAC King," is returning to Wall Street with a new blank-check deal. American Exceptionalism Acquisition Corp. filed a Form S-1 on Monday with the U.S. Securities and Exchange Commission, seeking to raise $250 million through an initial ...

Clover Health Investments's CLOV short percent of float has risen 12.43% since its last report. The company recently reported that it has 41.04 million shares sold short, which is 10.04% of all regular shares that are available for trading.

Clover Health's Q2 revenues rise 34%, but raised Insurance BER guidance and margin pressures cause shares to tumble post-earnings.

Clover Health Investments ( NASDAQ:CLOV ) , a technology-focused Medicare Advantage insurer, reported its Q2 2025 results on August 5, 2025. The most notable news was robust revenue growth, with GAAP sales climbing to $477.6 million-surpassing analyst expectations of $468.3 million ( GAAP ) .